A Study to Evaluate the Efficacy and Safety of Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy
Phase of Trial: Phase II
Latest Information Update: 31 Oct 2019
Price : $35 *
At a glance
- Drugs Dupilumab (Primary)
- Indications Peanut hypersensitivity
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 25 Apr 2019 Planned End Date changed from 6 Nov 2020 to 10 Nov 2020.
- 25 Apr 2019 Planned primary completion date changed from 11 Aug 2020 to 13 Aug 2020.
- 25 Apr 2019 Status changed from not yet recruiting to recruiting.